Journal article icon

Journal article

Comprehensive Integrated Analysis Reveals the Spatiotemporal Microevolution of Cancer Cells in Patients with Bone-Metastatic Prostate Cancer

Abstract:
Background/Objectives: Bone metastasis is a frequent and life-threatening event in advanced cancers, affecting up to 70–85% of prostate cancer patients. Understanding the cellular and molecular mechanisms underlying bone metastasis is essential for developing targeted therapies. This study aimed to systematically characterize the heterogeneity and microenvironmental adaptation of prostate cancer bone metastases using single-cell transcriptomics. Methods: We integrated the largest single-cell transcriptome dataset to date, encompassing 124 samples from primary prostate tumors, various bone metastatic sites, and non-malignant tissues (e.g., benign prostatic hyperplasia, normal bone marrow). After quality control, 602,497 high-quality single-cell transcriptomes were analyzed. We employed unsupervised clustering, gene expression profiling, mutation analysis, and metabolic pathway reconstruction to characterize cancer cell subtypes and tumor microenvironmental remodeling. Results: Cancer epithelial cells dominated the tumor microenvironment but exhibited pronounced heterogeneity, posing challenges for conventional clustering methods. By integrating genetic and metabolic features, we revealed key evolutionary trajectories of epithelial cancer cells during metastasis. Notably, we identified a novel epithelial subpopulation, NEndoCs, characterized by unique differentiation patterns and distinct spatial distribution across metastatic niches. We also observed significant metabolic reprogramming and recurrent mutations linked to prostate-to-bone microenvironmental transitions. Conclusions: This study comprehensively elucidates the mutation patterns, metabolic reprogramming, and microenvironment adaptation mechanisms of bone metastasis in prostate cancer, providing key molecular targets and clinical strategies for the precise treatment of bone metastatic prostate cancer.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Publisher copy:
10.3390/biomedicines13040909

Authors

More by this author
Role:
Author
ORCID:
0009-0001-9151-9515
More by this author
Role:
Author
ORCID:
0000-0002-5694-0101
More by this author
Role:
Author
ORCID:
0000-0003-1419-3168
More by this author
Role:
Author
ORCID:
0000-0002-4824-0930


More from this funder
Funder identifier:
https://ror.org/01h0zpd94
Grant:
81972400
82202962
More from this funder
Grant:
2021-12M-1-015
2022-12M-2-002
2023-12M-QJ-006
2022I2M-1-008


Publisher:
MDPI
Journal:
Biomedicines More from this journal
Volume:
13
Issue:
4
Pages:
909-909
Publication date:
2025-04-09
DOI:
EISSN:
2227-9059
ISSN:
2227-9059


Language:
English
Keywords:
Pubs id:
2329593
Local pid:
pubs:2329593
Source identifiers:
W4409326752
Deposit date:
2025-11-20
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP